William Blair Initiates Coverage On Janux Therapeutics with Outperform Rating

William Blair analyst Matt Phipps initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating.

byBenzinga Newsdesk

November 14, 2022

1 minute read

William Blair analyst Matt Phipps initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Outperform rating.

Ford Analyst Shares Takeaways From Meeting With Dearborn: The EV Split, Cost Pressures And More

By Wayne Duggan

Today, 1:36 PM

Bank of America auto analyst John Murphy recently hosted an investor meeting with management from Ford Motor Company (NYSE: F).

Iovance Biotherapeutics Announces First Patient Dosed With PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

By Bill Haddad

Today, 1:36 PM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the first patient was dosed, and completed the safety observation

IOVA

Nvidia Surges To Hit This Bellwether — Will The Stock Confirm A Bull Cycle?

By Melanie Schaffer

Today, 1:36 PM

NVIDIA Corp (NASDAQ: NVDA) declined over 3% when the market opened Thursday before spiking up over 3.4% from Wednesday’s closing price.

NVDA

Plus Therapeutics Announces Presentation Of ReSPECT-GBM Trial Dosimetery Data At American Society For Radiation Oncology (ASTRO) 2021 Annual Meeting

By Benzinga Newsdesk

Today, 1:36 PM

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today

PSTV

William Blair Initiates Coverage On Janux Therapeutics with Outperform Rating

Related Posts

Ford Analyst Shares Takeaways From Meeting With Dearborn: The EV Split, Cost Pressures And More

Iovance Biotherapeutics Announces First Patient Dosed With PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

Nvidia Surges To Hit This Bellwether — Will The Stock Confirm A Bull Cycle?

Plus Therapeutics Announces Presentation Of ReSPECT-GBM Trial Dosimetery Data At American Society For Radiation Oncology (ASTRO) 2021 Annual Meeting